The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Introduction: Stress has been shown to be a tumor promoting factor. Both clinical and laboratory studies have shown that chronic stress is associated with tumor growth in several types of cancer. Corticotropin Releasing Factor (CRF) is the major hypothalamic mediator of stress, but is also expressed in peripheral tissues. Earlier studies have shown that peripheral CRF affects breast cancer cell proliferation and motility. The aim of the present study was to assess the significance of peripheral CRF on tumor growth as a mediator of the response to stress in vivo. Methods: For this purpose we used the 4T1 breast cancer cell line in cell culture and in vivo. Cells were treated with CRF in culture and gene specific arrays were performed to identify genes directly affected by CRF and involved in breast cancer cell growth. To assess the impact of peripheral CRF as a stress mediator in tumor growth, Balb/c mice were orthotopically injected with 4T1 cells in the mammary fat pad to induce breast tumors. Mice were subjected to repetitive immobilization stress as a model of chronic stress. To inhibit the action of CRF, the CRF antagonist antalarmin was injected intraperitoneally. Breast tissue samples were histologically analyzed and assessed for neoangiogenesis. Results: Array analysis revealed among other genes that CRF induced the expression of SMAD2 and β-catenin, genes involved in breast cancer cell proliferation and cytoskeletal changes associated with metastasis. Cell transfection and luciferase assays confirmed the role of CRF in WNT- β-catenin signaling. CRF induced 4T1 cell proliferation and augmented the TGF-β action on proliferation confirming its impact on TGFβ/SMAD2 signaling. In addition, CRF promoted actin reorganization and cell migration, suggesting a direct tumor-promoting action. Chronic stress augmented tumor growth in 4T1 breast tumor bearing mice and peripheral administration of the CRF antagonist antalarmin suppressed this effect. Moreover, antalarmin suppressed neoangiogenesis in 4T1 tumors in vivo. Conclusion: This is the first report demonstrating that peripheral CRF, at least in part, mediates the tumor-promoting effects of stress and implicates CRF in SMAD2 and β-catenin expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stress, depression, the immune system, and cancer
Reiche, E. M. V., Nunes, S. O. V., & Morimoto, H. K. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01597-9 · Cited by 1,364 · cited 2×
“Discussion The impact of stress on the development of cancer has been widely proposed [1,2,36].”
BackgroundCRF and CRF receptors: role in stress responsivity and other behaviors
Bale, T. L., & Vale, W. W. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121410 · Cited by 1,270 · cited 1×
“In the tumor microenvironment, CRF is released by endothelial and immune cells and by the local neuronal innervation [9-11].”
BackgroundThe Kinase Akt1 Controls Macrophage Response to Lipopolysaccharide by Regulating MicroRNAs
Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zacharioudaki, V., Margioris, A. N., Tsichlis, P. N., & Tsatsanis, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.024 · Cited by 581
Self-citationThe actin cytoskeleton in cancer cell motility
Olson, M. F., & Sahai, E. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9174-2 · Cited by 572 · cited 1×
“This suggests that CRF could promote changes in cytoskeletal structures that allow cells to migrate and metastasize [45].”
BackgroundDevelopment of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549 · cited 4×
“Up-regulation of SMAD2, a downstream mediator of TGF-b signaling [28] was also confirmed by western blot analysis (Figure 4B, C).”
BackgroundInfluentialSignalling networks regulating cyclooxygenase-2
Tsatsanis, C., Androulidaki, A., Venihaki, M., & Margioris, A. N. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.021 · Cited by 492 · cited 1×
“Earlier studies from our group had shown that CRF induced Cox-2 expression [31], an enzyme known to promote angiogenesis via production of prostaglandins [32].”
BackgroundSelf-citationTheoharides, T. C., Singh, L. K., Boucher, W. S., Pang, X., Létourneau, R., Webster, E., & Chrousos, G. P. (1998) · Endocrinology · doi:10.1210/en.139.1.403 · Cited by 447
Neuroimmunoendocrine circuitry of the ‘brain-skin connection’
Paus, R., Theoharides, T. C., & Arck, P. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.10.002 · Cited by 343 · cited 1×
“CRF is the main hypothalamic stress-induced neuropeptide and its peripheral effect has also been reported in several systems [3,5,8,9,31,37-39].”
BackgroundCassoni, P., Papotti, M., Ghè, C., Catapano, F., Sapino, A., Graziani, A., Deghenghi, R., Reissmann, T., Ghigo, E., & Muccioli, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7402 · Cited by 329 · cited 2×
“Moreover, the effect of grelin on the phenotype depends on the expression of Estrogen Receptor [47,48].”
BackgroundWebster, E. L. (1996) · Endocrinology · doi:10.1210/en.137.12.5747 · Cited by 312 · cited 1×
“5. Evaluation of the in vivo model of chronic stress In order to greater extent the molecular mediators of CRF on tumor growth and the effect of peripheral CRF, we used an in vivo model of restraint stress (see Materials and methods) and antalarmin, a synthetic CRF1 receptor antagonist [ 33 ,34].”
MethodTaché, Y., & Perdue, M. H. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1743-3150.2004.00490.x · Cited by 282 · cited 3×
“In this regard, the CRF-based paracrine activity has been postulated to participate in the modulation of stress effects on the gastrointestinal system [ 5 ].”
BackgroundCassoni, P. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1738 · Cited by 185
Control of Actin Assembly Dynamics in Cell Motility
Carlier, M.-F., & Pantaloni, D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.r700020200 · Cited by 174 · cited 2×
“In addition, b-catenin is also involved in cytoskeletal changes characterized by actin polymerization, cell adhesion and motility [30].”
BackgroundAgelaki, S., Tsatsanis, C., Gravanis, A., & Margioris, A. N. (2002) · Infection and Immunity · doi:10.1128/iai.70.11.6068-6074.2002 · Cited by 170 · cited 2×
“In order to greater extent the molecular mediators of CRF on tumor growth and the effect of peripheral CRF, we used an in vivo model of restraint stress (see Materials and methods) and antalarmin, a synthetic CRF1 receptor antagonist [33,34].”
BackgroundMethodSelf-citationβ‐Catenin signaling in biological control and cancer
Gavert, N., & Ben‐Ze'ev, A. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21505 · Cited by 164 · cited 1×
“Regarding b-catenin, apart from being a cell-cell adhesion protein, is also an important signal transduction molecule in the Wnt signaling pathway [43].”
BackgroundPeripheral corticotropin-releasing hormone and urocortin in the control of the immune response
Baigent, S. (2001) · Peptides · doi:10.1016/s0196-9781(01)00395-3 · Cited by 146 · cited 2×
“In the tumor microenvironment, CRF is released by endothelial and immune cells and by the local neuronal innervation [9-11].”
BackgroundThe cardiovascular physiologic actions of urocortin II: Acute effects in murine heart failure
Bale, T. L., Hoshijima, M., Gu, Y., Dalton, N. D., Anderson, K. R., Lee, K., Rivier, J., Chien, K. R., Vale, W., & Peterson, K. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307324101 · Cited by 129 · cited 1×
“Moreover, CRF-related peptides exert direct actions on cardiomyocytes mediating the adaptive response of the cardiovascular system to stressful conditions such as ischemia and reperfusion [7,8].”
BackgroundCRH functions as a growth factor/cytokine in the skin
Slominski, A., Zbytek, B., Pisarchik, A., Slominski, R. M., Zmijewski, M. A., & Wortsman, J. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20530 · Cited by 128 · cited 2×
“Therefore using non malignant cells it has been shown that CRF stimulated dermal fibroblasts proliferation while it inhibited cell proliferation in keratinocytes [42].”
BackgroundResultJeffery, P. L., Murray, R. E., Yeh, A. H., McNamara, J. F., Duncan, R., Francis, G. D., Herington, A. C., & Chopin, L. K. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00984 · Cited by 119 · cited 1×
“Moreover, the effect of grelin on the phenotype depends on the expression of Estrogen Receptor [47,48].”
BackgroundCardiovascular actions of CRH and urocortin: an update
Parkes, D. G., Weisinger, R. S., & May, C. N. (2001) · Peptides · doi:10.1016/s0196-9781(01)00396-5 · Cited by 114
Kiank, C., Taché, Y., & Larauche, M. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.08.006 · Cited by 105 · cited 1×
“Indeed, multiple studies have shown that CRF mediates endocrine responses to stress, not only by activating the HPA axis but also via direct actions in the periphery [ 4-6 ].”
BackgroundWEBSTER, E. L., Barrientos, R. M., Contoreggi, C. S., Isaac, M. G., Ligier, S., Gabry, K. E., Chrousos, G. P., McCarthy, E. F., Rice, K. C., Gold, P. W., et al. (2002) · PubMed · Cited by 97
Psychosocial Stress Augments Tumor Development through β‐Adrenergic Activation in Mice
Hasegawa, H., & Saiki, I. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01313.x · Cited by 92 · cited 2×
“The impact of stress on the development of cancer has been widely proposed [ 1 ,2,36].”
BackgroundOxytocin inhibits proliferation of human breast cancer cell lines
Cassoni, P., Sapino, A., Negro, F., & Bussolati, G. (1994) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00197549 · Cited by 84 · cited 1×
“proliferation in breast cancer cell lines [46,47].”
Tsatsanis, C., Androulidaki, A., Dermitzaki, E., Gravanis, A., & Margioris, A. N. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.20900 · Cited by 83 · cited 2×
“Earlier studies from our group had shown that CRF induced Cox-2 expression [31], an enzyme known to promote angiogenesis via production of prostaglandins [32].”
BackgroundSelf-citationCorticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum
Wlk, M., Wang, C. C., Venihaki, M., Liu, J., Zhao, D., Anton, P. M., Mykoniatis, A., Pan, A., Zacks, J., Karalis, K. P., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34783 · Cited by 80 · cited 1×
“Indeed, earlier studies showed that intraperitoneal administration of antalarmin inhibited the proinflammatory role of CRF in toxin A-induced intestinal secretion and inflammation [49] or in the adjuvant induced arthritis model with Lewis rats [50].”
ResultSelf-citationThe corticotropin-releasing factor (CRF) family of peptides as local modulators of adrenal function
Tsatsanis, C., Dermitzaki, E., Venihaki, M., Chatzaki, Ε., MINAS, V., Gravanis, A., & Margioris, A. N. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6555-7 · Cited by 75 · cited 11×
“Our results confirmed that 4T1 cells expressed high levels of CRF1 receptor and very low levels of CRF2 receptor type b (CRF2b) (Figure 1).”
BackgroundInfluentialSelf-citationGraziani, G. (2002) · Endocrinology · doi:10.1210/en.143.3.807 · Cited by 70 · cited 3×
“In fact, previous studies from our group had shown that MCF7 breast cancer cells also express CRF1 receptor and low levels of CRF2 .H owever, in the present work we found that in 4T1 cells CRF induced cell proliferation, whereas in MCF7, and others cell lines such as the adenocarcinoma cell line Ishikawa and the human…”
BackgroundResultInfluentialCorticotropin-Releasing Hormone Family of Peptides Regulates Intestinal Angiogenesis
Im, E., Rhee, S. H., Park, Y. S., Fiocchi, C., Taché, Y., & Pothoulakis, C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.055 · Cited by 69 · cited 2×
“Interestingly, previous reports have shown a suppressive effect of Urocortin2 on tumor vascularization via CRF receptor 2 [51,52] and depletion of CRF1 in mice suppresses intestinal angiogenesis while ablation of CRF2 augments it, supporting a role for CRF1 signals in angiogenesis [ 35 ].”
BackgroundIntratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
MINAS, V., Rolaki, A., Kalantaridou, S., Sidiropoulos, J., Mitrou, S., Petsas, G. K., Jeschke, U., Paraskevaidis, E., Fountzilas, G., Chrousos, G. P., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603918 · Cited by 67 · cited 2×
“In addition, CRF induces local immunosuppression by promoting apoptosis of cytotoxic T-cell via the prduction of Fas ligand (FasL) in ovarian cancer cells [19].”
BackgroundUrocortin2 inhibits tumor growth via effects on vascularization and cell proliferation
Hao, Z., Huang, Y., Cleman, J., Jovin, I. S., Vale, W., Bale, T. L., & Giordano, F. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712366105 · Cited by 64 · cited 1×
“Interestingly, previous reports have shown a suppressive effect of Urocortin2 on tumor vascularization via CRF receptor 2 [51,52] and depletion of CRF1 in mice suppresses intestinal angiogenesis while ablation of CRF2 augments it, supporting a role for CRF1 signals in angiogenesis [35].”
BackgroundAnton, P. M., Gay, J., Mykoniatis, A., Pan, A., O'Brien, M., Brown, D., Karalis, K., & Pothoulakis, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402693101 · Cited by 64 · cited 1×
“Indeed, multiple studies have shown that CRF mediates endocrine responses to stress, not only by activating the HPA axis but also via direct actions in the periphery [4-6].”
BackgroundCorticotropin releasing factor promotes breast cancer cell motility and invasiveness
Androulidaki, A., Dermitzaki, E., Venihaki, M., Karagianni, E., Rassouli, O., Andreakou, E., Stournaras, C., Margioris, A. N., & Tsatsanis, C. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-30 · Cited by 58 · cited 8×
“Moreover, in the human breast cancer MCF7 cells, an estrogendependent tumor cell line, CRF inhibits cell proliferation but promotes motility and invasiveness via the activation of CRF1 [17,18].”
BackgroundResultInfluentialSelf-citationCorticotropin-Releasing Hormone Stimulates Angiogenesis and Epithelial Tumor Growth in the Skin
Arbiser, J. L., Karalis, K. P., Viswanathan, A. N., Koike, C., Anand‐Apte, B., Flynn, E. A., Zetter, B. R., & Majzoub, J. A. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00760.x · Cited by 57 · cited 2×
“In the tumor microenvironment, CRF is released by endothelial and immune cells and by the local neuronal innervation [9-11].”
BackgroundSlominski, A. T., Roloff, B., Zbytek, B., Wei, E. T., Fechner, K., Curry, J. L., & Wortsman, J. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036<0211:crharp>2.0.co;2 · Cited by 57 · cited 2×
“However, in the present work we found that in 4T1 cells CRF induced cell proliferation, whereas in MCF7, and others cell lines such as the adenocarcinoma cell line Ishikawa and the human HaCaT keratinocytes [18,24,25], proliferation was suppressed by CRF.”
BackgroundHirota, M., Watanabe, K., Hamada, S., Sun, Y., Strizzi, L., Mancino, M., Nagaoka, T., Gonzales, M., Seno, M., Bianco, C., et al. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.05.003 · Cited by 56
Kalantaridou, S. (2007) · Frontiers in Bioscience · doi:10.2741/2083 · Cited by 56 · cited 1×
“CRF is the main hypothalamic stress-induced neuropeptide and its peripheral effect has also been reported in several systems [3,5,8,9,31,37-39].”
BackgroundGraziani, G., Tentori, L., Muzi, A., Vergati, M., Tringali, G., Pozzoli, G., & Navarra, P. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.10.006 · Cited by 56 · cited 3×
“and the breast cancer cell line MCF7 [17,18,20,21,24].”
BackgroundSlominski, A. T., Roloff, B., Zbytek, B., Wei, E. T., Fechner, K., Curry, J. L., & Wortsman, J. (2000) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1071-2690(2000)036<0201:ahsemt>2.0.co;2 · Cited by 56
Radulović, M., Hippel, C., & Spiess, J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01594.x · Cited by 55 · cited 2×
“In contrast, in the Y79 retinoblastoma cell line CRF suppresses apoptosis via downregulation of pro-caspase 3 cleavage and activation [26] and in the B16F10 murine melanoma cell line it enhances cell migration through the ERK1/2 pathway [23].”
BackgroundWong, M., WEBSTER, E. L., Spokes, H., Phu, P., Ehrhart‐Bornstein, M., Bornstein, S. R., Park, C. S., Rice, K. C., Chrousos, G. P., Licinio, J., et al. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00268-4 · Cited by 54 · cited 2×
“Antalarmin was administered intraperitoneally and did not affect chronic stress-induced corticosterone levels ([27] and present report) but was able to inhibit its action on tumor cells.”
BackgroundMethodWang, J., Xu, Y., Xu, Y., Zhu, H., Zhang, R., Zhang, G., & Li, S. (2008) · Cancer Investigation · doi:10.1080/07357900701788106 · Cited by 53 · cited 1×
“Interestingly, previous reports have shown a suppressive effect of Urocortin2 on tumor vascularization via CRF receptor 2 [51,52] and depletion of CRF1 in mice suppresses intestinal angiogenesis while ablation of CRF2 augments it, supporting a role for CRF1 signals in angiogenesis [35].”
Backgroundvan Wijk, P. A., van Neck, J. W., Rijnberk, A., CROUGHS, R. J. M., & Mol, J. A. (1995) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03541-e · Cited by 47
Arranz, A., Androulidaki, A., Zacharioudaki, V., Martínez, C., Margioris, A. N., Gomariz, R. P., & Tsatsanis, C. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.023 · Cited by 46 · cited 1×
“5% agarose gel and visualized by ethidium bromide staining, or subjected to real-time PCR using SYBRgeen method as previously reported [54].”
MethodSelf-citationVenihaki, M. (1997) · Endocrinology · doi:10.1210/en.138.2.698 · Cited by 38 · cited 9×
“Moreover, in the human breast cancer MCF7 cells, an estrogendependent tumor cell line, CRF inhibits cell proliferation but promotes motility and invasiveness via the activation of CRF1 [17,18].”
BackgroundInfluentialSelf-citationThe corticotropin releasing factor system in cancer: expression and pathophysiological implications
Kaprara, A., Pazaitou‐Panayiotou, K., Kortsaris, A., & Chatzaki, Ε. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0265-2 · Cited by 38 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
BackgroundTezval, H., Jurk, S., Atschekzei, F., Becker, J. U., Jahn, O., Serth, J., & Kuczyk, M. A. (2009) · World Journal of Urology · doi:10.1007/s00345-009-0417-x · Cited by 37 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
BackgroundThe Expression of Corticotropin‐Releasing Hormone in Melanoma
Sato, H., Nagashima, Y., Chrousos, G. P., Ichihashi, M., & Funasaka, Y. (2002) · Pigment Cell Research · doi:10.1034/j.1600-0749.2002.1o063.x · Cited by 36 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
BackgroundKAT45, a Noradrenergic Human Pheochromocytoma Cell Line Producing Corticotropin-Releasing Hormone
Venihaki, M., Ain, K. B., Dermitzaki, E., Gravanis, A., & Margioris, A. N. (1998) · Endocrinology · doi:10.1210/endo.139.2.5724 · Cited by 35 · cited 2×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [ 20-22 ] a…”
BackgroundSelf-citationYang, Y., Park, H.-J., Yang, Y. D., Kim, T. S., Bang, S. I., & Cho, D. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00511.x · Cited by 34 · cited 3×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
BackgroundSáez, M. D. C., Barriga, C., García, J. J., Rodríguez, A. B., & Ortega, E. (2006) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-005-9067-5 · Cited by 33 · cited 1×
“The impact of stress on the development of cancer has been widely proposed [1,2, 36 ].”
BackgroundTezval, H., Jurk, S., Atschekzei, F., Serth, J., Kuczyk, M. A., & Merseburger, A. S. (2008) · The Prostate · doi:10.1002/pros.20892 · Cited by 32 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
BackgroundWillenberg, H. S., Haase, M., Papewalis, C., Schott, M., Scherbaum, W. A., & Bornstein, S. R. (2005) · Neuroendocrinology · doi:10.1159/000093126 · Cited by 30 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
Backgroundβ-Catenin/LEF-1 Signalling in Breast Cancer – Central Players Activated by a Plethora of Inputs
Gebeshuber, C. A., Sladecek, S., & Grünert, S. (2007) · Cells Tissues Organs · doi:10.1159/000101303 · Cited by 23
Pournajafi‐Nazarloo, H., Buttrick, P. M., Saadat, H., & Dunn, A. (2006) · Current Protein and Peptide Science · doi:10.2174/138920306777452358 · Cited by 22 · cited 2×
“CRF is the main hypothalamic stress-induced neuropeptide and its peripheral effect has also been reported in several systems [3,5, 8 ,9,31,37-39].”
BackgroundCorticotropin-releasing hormone receptor-1 in human endometrial cancer
Graziani, G., Ferrandina, G., Pozzoli, G., Vergati, M., Muzi, A., Legge, F., Tentori, L., Scambia, G., & Navarra, P. (2006) · Oncology Reports · doi:10.3892/or.15.2.375 · Cited by 16 · cited 1×
“Moreover, peptides of the CRF family and their receptors have been also found expressed by several cancer cells [12], such as human renal cell carcinoma [13], tumorous adrenocortical cells [14], human endometrial, prostate, ovarian and breast cancer cells [14-19], human pheochromocytoma cells and melanomas [20-22] and…”
Backgroundvan Wijk, P. A., Rijnberk, A., CROUGHS, R. J. M., Meij, B. P., & Mol, J. A. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1380309 · Cited by 14
Cited by
Chronic Stress Promotes Cancer Development
Dai, S., Mo, Y., Wang, Y., Xiang, B., Liao, Q., Zhou, M., Li, X., Li, Y., Xiong, W., Li, G., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01492 · Cited by 405
“The antagonist of CRF, antalarmin, inhibits neovascularization in 4T1 breast cancer cell lines in vivo (43).”
BackgroundDu, P., Zeng, H., Xiao, Y., Zhao, Y., Zheng, B., Deng, Y., Liu, J., Huang, B., Zhang, X., Yang, K., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02981-1 · Cited by 81
Zhang, J., Gan, L., Wu, Z., Yan, S., Liu, X., & Guo, W. (2016) · Oncotarget · doi:10.18632/oncotarget.7399 · Cited by 58
“reported that peripheral CRF contributed to proliferation and metastasis of tumors, by means of altering the expression of SMAD2, β-catenin, and cytoskeletal genes.[38] As proangiogenic factors that play a considerable role in neovascularization and development of GC[39–41], lower levels of VEGF and IL-6 are shown to…”
BackgroundAnalgesics promote welfare and sustain tumour growth in orthotopic 4T1 and B16 mouse cancer models
Lofgren, J. L. S., Miller, A. L., Lee, C. C. S., Bradshaw, C., Flecknell, P. A., & Roughan, J. V. (2017) · Laboratory Animals · doi:10.1177/0023677217739934 · Cited by 37
Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1α Signaling
Liu, H., Yang, J., Zhang, Y., Han, J., Yang, Y., Zhao, Z., Dai, X., Wang, H., Ding, X., Liu, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1043 · Cited by 37
“growth in a chronic-stress mouse model (25).”
Metadata
- Authors
- Arranz, A., Venihaki, M., Mol, B., Androulidaki, A., Dermitzaki, E., Rassouli, O., Ripoll, J., Stathopoulos, E. N., Gomariz, R. P., Margioris, A. N., & Tsatsanis, C.
- Affiliations
- University of Crete (GR)
- Foundation for Research and Technology Hellas (GR)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Margioris, Andrew N
- Tsatsanis, Christos
- Venue
- Molecular Cancer
- Published
- 2010-09-27
- Volume
- 9
- Issue
- 1
- Pages
- 261-261
- ISSN
- 1476-4598 (ISSN-L)
- PMC
- PMC2956730
- OpenAlex
- W2116390790
- Cited by
- 30
- References
- 56
- Citations by year
- 2026: 3 · 2025: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 4 · 2013: 2
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Molecular Cancer (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Defense
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- corticotropin-releasing factor, chronic stress, tumor growth, breast cancer, 4T1 cells, antalarmin, Wnt/β-catenin signaling, Smad2, TGF-β/Smad2 signaling, cell proliferation, cell migration, actin reorganization, neoangiogenesis, restraint stress
- MeSH terms
- Animals, Breast Neoplasms, Cell Movement, Cell Survival, Corticotropin-Releasing Hormone, Female, Fluorescent Antibody Technique, Mice, Inbred BALB C, Pyrimidines, Pyrroles, Radioimmunoassay, Stress, Physiological, Blotting, Western, Gene Expression Regulation, Neoplastic, Reverse Transcriptase Polymerase Chain Reaction, Cell Line, Tumor, Cell Proliferation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.